Jakarta, October 16, 2025 – PT Kalbe Farma Tbk (Kalbe), through its subsidiary PT Bintang Toedjoe, welcomed a delegation from the International Regulatory Cooperation for Herbal Medicines (WHO–IRCH) as part of the Sixteenth Annual Meeting of the World Health Organization held in Jakarta. On this occasion, WHO expressed its appreciation to Bintang Toedjoe for demonstrating a strong commitment to the development of modern herbal medicines. The visit, which was also accompanied by representatives from the Indonesian Food and Drug Authority (Indonesian FDA), served as further proof of Bintang Toedjoe’s dedication to enhancing its contribution to Indonesia’s natural-based pharmaceutical development.

“This visit reflects our shared commitment to fostering international collaboration in the research and standardization of herbal medicines. As part of Kalbe Group, PT Bintang Toedjoe is fully committed to maintaining both national and international standards. All our facilities are certified for CPOBAB/CPOTB (Good Manufacturing Practices for Natural-Based Medicines), ISO 9001, ISO 14001, and ISO 45001,” said Irawati Setiady, President Director of PT Kalbe Farma Tbk.

Irawati further stated that she believes synergy among government bodies, industries, research institutions, academia, and international organizations such as WHO is the key to building a better health future. With the support of WHO and Indonesian FDA, the company aims to further strengthen its quality assurance systems, deepen scientific research, and broaden its contribution to the development of safe, effective, and sustainable herbal products.

She also emphasized Kalbe and Bintang Toedjoe’s deep appreciation for WHO and BPOM’s support, particularly regarding the implementation of Good Manufacturing Practices for Herbal Medicines (GMP) or CPOBAB/CPOTB, which serve as the foundation for all production processes.

“WHO–IRCH serves as a global platform to strengthen collaboration and regulatory convergence in the field of herbal medicines. We greatly appreciate Indonesia’s leadership and the commitment of its industry, particularly PT Bintang Toedjoe, in advancing high-quality herbal medicinal products,” said Dr. Kim Sungchol, Head of WHO–IRCH.

Bintang Toedjoe’s achievements have also received full support from the Indonesian FDA. The Deputy of Traditional Medicines, Health Supplements, and Cosmetic Control, Apt. Mohamad Kashuri, S.Si., M.Farm., expressed his appreciation for Bintang Toedjoe’s innovation in building a comprehensive red ginger ecosystem.

“ Our sincere appreciation goes to PT Bintang Toedjoe for making a remarkable breakthrough in innovation by establishing a comprehensive red ginger ecosystem, featuring this original Indonesian herbal commodity. This initiative involves the active collaboration of farmers, the private sector, educational institutions, and government bodies. The company has successfully carried out innovative developments of red ginger–based products, which are now distributed globally,” said Apt. Mohamad Kashuri, S.Si., M.Farm.

He also explained the vital role of WHO–IRCH as an international cooperation platform to strengthen the capacity of national regulatory authorities in the field of herbal medicines, as well as to support WHO in providing recommendations to its member states. “This effort not only ensures the quality, safety, and efficacy of herbal medicines but also to facilitate the evidence-based integration of herbal medicines into national health systems,” he added.

Bintang Toedjoe has transformed into one of Indonesia’s leading herbal industries, focusing on the development of scientifically validated and safe natural-based products. “We have also established an integrated red ginger ecosystem – from seed cultivation and farming with our partner farmers to post-harvest processing, extraction, distillation, research, and product commercialization. This approach not only ensures high-quality raw materials but also supports the sustainability of local communities,” explained Irawati.

“It is an honor for us to welcome WHO–IRCH and Indonesian FDA. This recognition is a testament to   PT Bintang Toedjoe’s commitment to maintaining the highest standards in regulation, quality, and sustainable innovation for the advancement of Indonesia’s herbal medicine industry. The visit reinforces our spirit to continue innovating and meeting global standards in developing safe, effective, and halal herbal products for the global community,” said Fanny Kurniati, President Director of PT Bintang Toedjoe.

Fanny emphasized that through the spirit of “From Nature to Science,” Bintang Toedjoe continues to deliver innovations driven by scientific research. Products such as Bejo Jahe Merah and Komix Herbal are tangible evidence that local wisdom can be developed into globally competitive health products.

As one of the most biodiverse countries in the world, Indonesia holds tremendous potential in developing natural resources such as red ginger — the core focus of Bintang Toedjoe’s leading research. WHO recognizes this potential as strategic in supporting the concept of “Local Wisdom for Global Health,” which transforms local natural ingredients into herbal products that meet global standards of safety, efficacy, and quality.

The WHO–IRCH site visit is expected to serve as a significant momentum to strengthen Indonesia’s position as a hub for the development and production of internationally standardized herbal medicines. Moreover, it provides an opportunity for knowledge exchange to foster innovation, sustainability, and global competitiveness in the national herbal industry.

About PT Bintang Toedjoe

PT Bintang Toedjoe is a leading pharmaceutical and herbal product company in Indonesia, established in 1946 and a subsidiary of the Kalbe Group. For over seven decades, Bintang Toedjoe has consistently delivered high-quality health innovations such as Bejo Jahe Merah, Komix Herbal, and Extra Joss, all rooted in scientific research and Indonesia’s rich natural heritage.

Guided by the spirit of “Innovation for a Better Life,” the company continues to transform into an adaptive, sustainability-oriented organization actively engaged in social responsibility initiatives in health, environment, and community empowerment. For more information, please visit: https://www.bintang7.com

About Kalbe

PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the largest publicly listed pharmaceutical companies in Southeast Asia. Kalbe operates four main divisions managing a robust and diverse brand portfolio: prescription pharmaceuticals, consumer health products (OTC and multivitamins), nutritionals, and distribution & logistics.

Kalbe has also developed B2B digital service ecosystems such as EMOS and MOSTRANS. EMOS is an order management application that simplifies stock and supply chain management for distribution channels, while MOSTRANS provides B2B transportation solutions for efficient logistics management.

Today, Kalbe has more than 49 subsidiaries and 14 internationally certified manufacturing facilities, supported by around 16,000 employees across 71 branches throughout Indonesia. Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).
For more information, please visit: https://www.kalbe.co.id